Agustin Albillos

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 259 publications

Impact factor enshittification: Reflections on metrics, incentives and scientific publishing.

Impact factor enshittification: Reflections on metrics, incentives and scientific publishing.

Journal: Annals of hepatology

Published: July 10, 2026

Corrigendum to 'Pre-emptive TIPS should be considered in high-risk patients with both acute variceal bleeding and severe alcohol-related hepatitis' (JHEP Reports 7 [2025] 101611).

Corrigendum to 'Pre-emptive TIPS should be considered in high-risk patients with both acute variceal bleeding and severe alcohol-related hepatitis' (JHEP Reports 7 [2025] 101611).

Journal: JHEP reports : innovation in hepatology

Published: March 08, 2026

Reply to: Correspondence on "Early portopulmonary hypertension predicts mortality in patients with cirrhosis: Insights from the PORTO-DETECT cohort": Early portopulmonary hypertension: A signal of increased mortality risk in cirrhosis.

Reply to: Correspondence on "Early portopulmonary hypertension predicts mortality in patients with cirrhosis: Insights from the PORTO-DETECT cohort": Early portopulmonary hypertension: A signal of increased mortality risk in cirrhosis.

Journal: Journal of hepatology

Published: February 09, 2026

Multicenter, double-blind, sham endoscopy-controlled, randomized trial evaluating the efficacy of anti-reflux mucosal ablation for the treatment of gastro-esophageal reflux disease.

Multicenter, double-blind, sham endoscopy-controlled, randomized trial evaluating the efficacy of anti-reflux mucosal ablation for the treatment of gastro-esophageal reflux disease.

Journal: Endoscopy

Published: December 31, 2025

Multicenter, double-blind, sham endoscopy-controlled, randomized trial evaluating the efficacy of antireflux mucosal ablation for the treatment of gastroesophageal reflux disease.

Multicenter, double-blind, sham endoscopy-controlled, randomized trial evaluating the efficacy of antireflux mucosal ablation for the treatment of gastroesophageal reflux disease.

Journal: Endoscopy

Published: December 31, 2025

A search for patient-centered strategic alliances between the specialties of Gastroenterology and Hospital Pharmacy: the CONDIFA project.

A search for patient-centered strategic alliances between the specialties of Gastroenterology and Hospital Pharmacy: the CONDIFA project.

Journal: Revista espanola de enfermedades digestivas

Published: December 18, 2025

Hepatic venous pressure gradient, non-invasive tests, and prognosis across the subtypes of advanced steatotic liver disease.

Hepatic venous pressure gradient, non-invasive tests, and prognosis across the subtypes of advanced steatotic liver disease.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: December 11, 2025

Hepatic Venous Pressure Gradient, Noninvasive Tests, and Prognosis Across the Subtypes of Advanced Steatotic Liver Disease.

Hepatic Venous Pressure Gradient, Noninvasive Tests, and Prognosis Across the Subtypes of Advanced Steatotic Liver Disease.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: December 11, 2025

Biological therapies for inflammatory pouch disorders: insights and outcomes from the RESERVO study of GETECCU.

Biological therapies for inflammatory pouch disorders: insights and outcomes from the RESERVO study of GETECCU.

Journal: Therapeutic advances in gastroenterology

Published: October 14, 2025

Goblet-cell muscarinic signaling at the gut barrier: A therapeutic checkpoint/target in alcohol-related liver disease.

Goblet-cell muscarinic signaling at the gut barrier: A therapeutic checkpoint/target in alcohol-related liver disease.

Journal: JHEP reports : innovation in hepatology

Published: October 01, 2025

Prognostic value of factor VIII, D-dimer and high molecular risk variants assessing re-thrombosis risk in non-cirrhotic portal vein thrombosis.

Prognostic value of factor VIII, D-dimer and high molecular risk variants assessing re-thrombosis risk in non-cirrhotic portal vein thrombosis.

Journal: JHEP reports : innovation in hepatology

Published: August 18, 2025

Clinical Perspectives on Long-Term Albumin Therapy in Decompensated Cirrhosis: A Nationwide Delphi Survey in Spain-The ALBA Study.

Clinical Perspectives on Long-Term Albumin Therapy in Decompensated Cirrhosis: A Nationwide Delphi Survey in Spain-The ALBA Study.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: July 27, 2025

Showing 1-12 of 259

Last Updated: 09/26/2026